Clinical Trial Details

Overview

Research Study Summary

Reveal

Purpose

Prospective, single arm, open-label, multicenter, post-market interventional clinical study to determine, via continuous monitoring with the Reveal XT implantable cardiac monitor (ICM), the incidence of atrial fibrillation (AF) in patients suspected to be at high risk for having AF and to understand how physicians manage these patients once AF has been detected.

To Learn more

CW ID: 192264
Date Last Changed: November 22, 2013

Clinical Trial Snapshot

Gender
Both Male and Female
Age
N/A
Overall Status
Recruiting
Facility Type
Out-Patient

Eligibility

Inclusion Criteria:

  • Patient is suspected of having Atrial Fibrillation (AF) or at high risk of having AF
  • Patient has a CHADS2 (Congestive heart Failure, HTN, Age >75, Diabetes Mellitus, prior Stroke) score = 3 OR has a CHADS2 score = 2 with at least one of the following documented:
    • Coronary artery disease
    • Renal impairment (GFR 30-60 ml/min)
    • Sleep apnea
    • Chronic obstructive pulmonary disease

Exclusion Criteria:

  • Documented history of AF or Atrial Flutter
  • Ischemic Stroke or TIA within past year prior to enrollment
  • History of a Hemorrhagic Stroke

Contact

Adriana Valencia, Research Study Coordinator
Baylor Scott & White Research Institute
3310 Live Oak Street
Dallas, TX 75204
Phone: 469-814-4733

View Map

Research Center Information:

Baylor Scott & White Research Institute

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.